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Introduction: Endovascular treatment for atherosclerotic renal artery stenosis (ARAS) was first performed>30 years ago
and its use has increased rapidly since then. However, only recently have large randomized trials rigorously evaluated its
clinical benefit.
Methods: We systematically reviewed the controlled studies on primary stenting for atherosclerotic renal artery stenosis.
Studies were included if they compared the outcome of stenting with other treatments, or the outcome associated with
different stent characteristics or stenting methods.
Results: Stenting is preferred over angioplasty alone and over surgery when revascularization is indicated for ostial ARAS,
except in cases of coexistent aortic disease indicating surgery. Randomized controlled trials showed no significant benefit
and substantial risk of renal artery stenting over medication alone in patients with atherosclerotic ARAS without a
compelling indication. Improvements in the procedure, such as with distal embolic protection devices and coated stents,
are not associated with better clinical outcomes after stent placement for ARAS.
Conclusion: Recent evidence shows that impaired renal function associated with ARAS is more stable over time than
previously observed. Optimal medical treatment should be the preferred option for most patients with ARAS. Only
low-level evidence supports compelling indications for revascularization in ARAS, including rapidly progressive hyper-
tension or renal failure and flash pulmonary edema. (J Vasc Surg 2010;51:1574-80.)Atherosclerotic renal artery stenosis (ARAS) may lead
to hypertension, impaired renal function, and cardiac dis-
orders, including flash pulmonary edema, uncontrolled
heart failure, or unstable angina pectoris. Since the first
report of ARAS angioplasty 30 years ago, endovascular
approaches have supplanted surgical approaches for revas-
cularization. However, few data are available to guide
medical decisions in the treatment of ARAS. The objective
of this review was to summarize the available evidence on
primary stent placement for ARAS.
METHODS
Many uncontrolled retrospective and prospective co-
hort studies of stent placement for ARAS have been pub-
lished. However, owing to the lack of control groups, their
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1574results fail to provide a sound basis for medical decision
making. We therefore limited our review to studies that
compared renal artery stenting with other treatment op-
tions for ARAS or that compared different procedural
strategies. We searched Medline, the Cochrane Central
Register of Controlled Trials, and ClinicalTrials.gov with
combinations of the following keywords: renal artery ob-
struction, renal artery stenosis, renovascular disease, renovas-
cular hypertension, ischemic nephropathy, stent, and endovas-
cular. We also screened reference lists of original articles,
guidelines, and reviews. Levels of evidence were rated using
a scale provided by the Journal of Vascular Surgery (Appen-
dix 1, online only).
RESULTS
Benefit of renal artery stenting over angioplasty.
ARAS predominantly involves the proximal third of the artery
and is prone to restenosis after angioplasty alone. Primary
stenting in ARAS was compared with the use of angioplasty
alone in both a nonrandomized study1 and a randomized
controlled trial2 (RCT; Table I). The results were consistent
with those of a meta-analysis that indirectly compared these
treatment strategies:4 procedural successwas higher and reste-
nosis rate was lowerwith stenting thanwith angioplasty alone,
but clinical outcomedid not differ significantly. Findings from
the RCT suggest that to ensure long term patency, reinter-
vention would be needed in 57% of patients after angioplasty
alone but only in 12% of patients after primary stenting.2
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cost-efficacy profile and lower risk-benefit ratio than angio-
plasty alone for ARAS that requires intervention.5
Benefit of renal artery stenting vs surgery. One
RCT compared endovascular stenting with open surgical
Table I. Studies comparing stent placement with other in
Reference Design (years) LOE
Primary stent vs angioplasty
alone
Van de Ven,2 1999 RCT (1993-1997) I
Baumgartner,1 2000 Prospective (1994-1998) II-2
Stent vs surgery
Balzer,3 2009 RCT (1998-2004) I
ACEI, Angiotensin-converting-enzyme inhibitors; BP, blood pressure; LOE
Table II. Studies comparing stent placement with medica
Reference Design (years) LOE
ASTRAL,10 2009 RCT (2000-2007) I Unco
imp
STAR,8 2009 RCT (2000-2005) I Impa
Ziakka,9 2008 RCT (Not stated) II-1 Hype
Zalunardo,7 2008 Retrospective (2001-2005) II-2 Coro
hyp
or p
Arthurs,6 2007 Retrospective (2001-2006) II-2 Unco
ren
AC
ACEI, Angiotensin-converting-enzyme inhibitors; BP, blood pressure; LOE
aGlomerular filtration rate (GFR) , mL/min/1.73m2; serum creatinine (SCreconstruction in ARAS patients without concurrent aorticdisease.3 No significant difference in treatment outcome
was found, but surgery was associated with a longer initial
hospitalization (Table I). This study thus suggests that
stenting should generally be the preferred revascularization
technique and that surgery should be limited to patients
ntions for atherosclerotic renal artery stenosis
Inclusion criteria Stenosis
Mean renal function
SCr (mg/dL)
rtension  positive renography
a rise in creatinine 20% on
EI
50% 1.8
rtension 60% 2.0
rtension 70% 1.45
l of evidence; RCT, randomized-controlled trial; SCr, serum creatinine.
alone for atherosclerotic renal artery stenosis
Inclusion criteria Stenosis
Renal
functiona
led hypertension or unexplained
renal function
50% GFR 40
enal function but stable BP 50% GFR 45
on Mean 74% SCr 2.3
raphy and uncontrolled
sion, unexplained renal failure
nary edema
50% GFR 55
led hypertension, worsening
ction, cardiac disturbance, or
tolerance
60% SCr 1.5 (stent),
1.0 (medic)
l of evidence; NS, not significant; RCT, randomized-controlled trial.
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tion alone. Two small nonrandomized studies6,7 and two
RCTs of limited power8,9 compared stent placement with
secondary prevention treatment alone (antihypertensive
agents, statins, and aspirin) in ARAS patients with difficult-
Table I. Continued.
Mean BP
(mm Hg)
Bilateral
treatment Patients, No.
Fo
(mea
186/103 21% 41 patients (stent); 40 patients
(angioplasty)
179/95 37% 163 patients; 70 arteries (stent);
130 arteries (angioplasty)
170/88 22% (stent),
81% (surgery)
22 patients (stent); 27 patients
(surgery)
5
Table II. Continued.
Mean BP
(mm Hg)
Bilateral
treatment Intervention; control
151/76 (or solitary kidney)
20%
Stent; discretionary
medication
160/82 46% Stent; semi-standardized
medication
176/89 34% ( 5% solitary
kidney)
Stent; discretionary
medication
158/73 (stent),
142/73 (medic)
40% (stent), 21%
(medic)
Stent if uncontrolled
hypertension,
worsening renal
function, pulmonary
edema, or ACEI
sensitivity
162/75 (stent),
142/73 (medic)
58% No stent if inadequate
antihypertensive
regimen, poor patient
compliance, acute
medical condition,
resistance index 0.80
or stenosis 70%to-treat hypertension or unexplained impairment of renalfunction. Overall, these studies did not show a clinically
meaningful improvement in blood pressure control or renal
function stabilization in patients receiving stents (Table II).
The results of the much larger Angioplasty and Stent
for Renal Artery Lesions (ASTRAL) RCT further question
up
nths) Outcomes
65% relative reduction in risk of restenosis with stents at
6-month angiography (P  .001). No difference in BP
or renal outcome
70% relative reduction in risk of restenosis with stents for
ostial stenoses at 12 months ultrasound study (P 
.002). No comparative data on BP and renal outcome
6 Initial hospitalization: 10 days for stenting and 18 days for
surgery. No difference in frequency of complications, in
long-term patency, BP or renal outcome
atients, No.
Follow-up
(mean months) Outcomes
3 stent; 403
o stent
34 No difference in renal function
decline, renal event-free
survival, BP, cardiovascular
event-free survival or overall
survival, regardless of
baseline GFR, baseline GFR
decline rate, severity of renal
artery stenosis, and severity
of anatomic disease
stent; 46
o stent
24 No difference in renal event-
free survival, in BP outcome
or overall survival
stent; 36
o stent
48 Renal function improved in
31% with stent vs 0% with
medication (P  .001), but
improved or stabilized in
64% with stent vs 70% with
medication (NS)
stent; 73
o stent
38 stent; 27 medic No difference in renal function
decline
stent; 22
o stent
15 No difference in overall and
coronary event free survival.
No difference in 6 months
BP outcome. Stabilization
of renal function with stent,
especially if pre-existing
renal dysfunction (P  .05
vs medication alone)llow-
n mo
6
9
4 to 9P
40
n
45
n
46
n
67
n
,
18
nthe benefit of ARAS stenting vs medical therapy.10 Change
(mL/
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significantly between the two strategies. Numbers of deaths
and cardiovascular events were also similar in both study
groups, but the confidence intervals (CI) of hazard ratios
could not exclude relevant differences in clinical outcome:
0.90 (95% CI, 0.69-1.18) for overall survival and 0.94
(95% CI, 0.75-1.19) for cardiovascular event-free survival.
A cohort study evaluated the change in left ventricular
mass (LVM) after stent placement in patients with ARAS
and hypertension or impaired renal function.11 Patients
with essential hypertension were the controls. After adjust-
ment for various potential confounding variables, the re-
sults suggested a beneficial effect of stent placement on
LVM that could not be fully accounted for by the observed
reduction in blood pressure. A comparative study in pa-
tients with ARAS was unable to confirm this benefit, but it
was grossly under-powered, with only eight patients in the
stent group.12 The undergoing ASTRAL heart substudy13
and the RADAR (Randomized, Multi-Centre, Prospective
Study Comparing Best Medical Treatment Versus Best
Medical Treatment Plus Renal Artery Stenting in Patients
With Hemodynamically Relevant Atherosclerotic Renal
Artery Stenosis) study14 were designed to properly assess
cardiac outcomes after stent placement.
Stent placement is a minimally invasive procedure, but
patients with ARAS are frail and prone to complications.
The proportion of patients in ASTRAL who experienced at
least one adverse event was 9% during the first 24 hours
after stent placement and 20% between 2 and 30 days after
the procedure; overall, 6% experienced serious complica-
tions related to revascularization.10 Appendix 2 (online
Table III. Evaluation of procedural improvements for ste
Reference Design (years)
With vs without protection device
Cooper,17,18 2008 RCT (2002-2007)
Singer,16 2008 Retrospective (2002-20
Bare stents vs coated stents
Zeller,19 2003 Prospective (1996-2000
Zeller,20 2005 Prospective (2002-2004
Zahringer,21 2007 Prospective (2001-2003
Nolan,22 2005 Retrospective (2000-20
BP, Blood pressure; CI, confidence interval; GFR, glomerular filtration rateonly) lists the adverse events reported in 22 large prospec-tive cohorts (3453 patients) after stent placement for
ARAS15 and in the ASTRAL trial.
Procedure improvements. In some patients, acute de-
terioration of renal function after stent placement may be due
to contrast-induced nephropathy and atheroembolism. Pro-
phylactic treatment for contrast nephropathy should therefore
be considered. Effective antithrombotic treatment and use of
distal embolic protection devices during the procedure could
prevent the consequences of atheroembolism. However, a
comparative study16 and aRCT17,18 did not find any convinc-
ing beneficial effect of protection devices on clinical outcome
(Table III). In the RCT, no change was seen in glomerular
filtration rate after intervention in a small patient subgroup
that received abciximab and adistal protectiondevice,whereas
glomerular filtration rate declined in the other three groups.
Restenosis occurred in 10% to 21% of patients studied
during a follow-up period of 3 to 40 months after stent
placement for ARAS.15 Optimal long-term antithrombotic
treatment and coated stents may improve these rates. Patients
usually receive long-term treatment with antiplatelet agents
after stent placement. The United States multicenter trial
found no beneficial effect of 3-month warfarin treatment after
the procedure.23 Four comparative studies showed no im-
provement in restenosis rate and clinical outcome with gold-,
carbon- or sirolimus-coated stents19-22 (Table III).
DISCUSSION
The past decade has seen the development of highly
effective treatment regimens in patients with atherosclero-
sis that also exert a protective effect on renal function in
patients with ARAS. Renal function decline was very grad-
acement in atherosclerotic renal artery stenosis
LOE Inclusion criteria
I Hypertension, renal failure, or cardiac
destabilization
II-2 GFR 60 and anatomic eligibility for the use
of a protection device
II-1 Hypertension
II-1 Hypertension
II-1 Hypertension and non-severe renal failure
II-2 Difficult to treat hypertension or chronic
renal failure
min/1.73 m2); HR, hazard ratio; LOE, level of evidence.nt pl
05)
)
)
)
03)ual in patients in ASTRAL, even in those with severe
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stent placement should be the preferred option for asymp-
tomatic patients or for patients who do not have a compel-
ling clinical indication for revascularization, including ac-
celerated hypertension, unexplained rapidly declining renal
function, declining renal function after the administration
of angiotensin-converting-enzyme (ACE) inhibitors, or
flash pulmonary edema.
Outcome after renal artery stenting in specific sub-
groups. However, the basis for this recommendation
comes from comparative studies that included heteroge-
neous populations, including some patients with stenosis of
debatable hemodynamic significance. Overall negative re-
sults do not exclude the possibility that several subgroups of
patients may benefit from stenting.
There are clues suggesting that hypertension or im-
paired renal function in a patient are consequences of ARAS
rather than merely associated essential hypertension or
nephrosclerosis. As such, rapidly deteriorating renal func-
tion or worsening hypertension control, low renal resis-
tance index, low proteinuria, and severe stenosis, particu-
larly affecting both renal arteries or a solitary kidney, are
considered predictors of good outcome after stent place-
ment. However, these predictive factors were established
from cohort studies, often with defective methods and
showing conflicting results. Moreover, even if they truly
predict a better response to stent placement, they may also
predict a better response to optimized medical treatment.
Only comparative studies can definitely assess the relative
efficacy of both treatment strategies in specific subgroups.
Severe stenosis, for example, is thought to justify
Table III. Continued.
Stenosis Patients, No.
F
(me
50% 100 randomized in 2  2 groups:
with or without filter; with or
without abciximab
Not stated 31: various protection devices;
17: no protection device
70% 54: gold-coated stent; 117:bare-
metal stent
70% 68: carbon-coated stent; 57: bare-
metal stent
50% 53: sirolimus-coated stent; 52:
bare-metal stent
U
75%; or systolic trans-
stenotic gradient
15 mm Hg
44: gold-coated stent; 33: bare-
metal stenta more aggressive approach than moderate stenosis.ASTRAL, however, showed no difference in outcome
between ARAS subgroups of varying severity.10 Further-
more, a post hoc analysis showed very gradual renal
function decline in 163 patients with70% ARAS on both
sides or affecting a solitary kidney, with a similar outcome
observed for patients treated medically and those treated
with stent placement.
Similarly, a high renal resistance index is considered as a
marker of severe nephrosclerosis. An often-cited study
found that a renal resistance index0.8 was associated with
poor blood pressure and renal outcome in ARAS treated by
revascularization, predominantly involving angioplasty
alone.24 However, more recent prospective studies of
ARAS treated with stent placement were unable to replicate
this finding.25,26 Some studies even showed improved renal
function27 or blood pressure28 after stent placement in
patients with a high renal resistance index. The ongoing
Cardiovascular Outcomes in Renal Atherosclerotic Lesions
(CORAL) study should provide a definitive answer to this
issue.29
The benefit of stenting still has to be properly evaluated
in patients with the aforementioned compelling indications
who have been explicitly or implicitly excluded from RCTs.
Cohort studies strongly suggest that ARAS patients with
deteriorating renal function after the administration of
ACE inhibitors or angiotensin-receptor blockers may tol-
erate them better after stent placement if they are neces-
sary.30-33 No published reports have compared current
optimized medical treatment to stent placement in patients
with flash pulmonary edema, uncontrolled heart failure, or
unstable angina pectoris; however, a pathophysiologic ra-
-up
onths) Outcomes
No difference in procedural and BP outcome. No overall
difference in renal outcome but a significant
improvement in the group randomized to filter 
abciximab. Similar outcomes whether distal embolic
protection was complete or incomplete (at least one
renal artery branch not protected)
No difference in BP and renal outcomes at 6 or 12
months
No difference in primary success rate or 12 months
restenosis rate. No data on BP and renal outcome
No difference in primary success or 12-month restenosis
rate. No data on BP and renal outcome
24 No difference in 6-month restenosis rate (systematic
control angiography) or later restenosis. No difference
in BP or renal outcome at 6, 12 and 24 months
No difference in primary success rate, but significantly
more restenosis with gold-coated stents after
12-month (HR, 3.3; 95% CI, 1.2-8.7). Improved BP
in 77% with gold-coated stents vs 87% with bare metal
stents (P  .04); no difference in renal outcomeollow
an m
1
12
12
22
p to
12tionale and the dramatic results of small series30,34,35 have
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ment.4
Perspectives. CORAL29 and RADAR14 are the two
largest ongoing RCTs registered under ClinicalTrials.gov
evaluating the benefit of stent placement compared with
current best medical treatment. CORAL plans to enroll
1080 patients with ARAS 60% and hypertension or renal
dysfunction. The primary end point is cardiovascular and
renal event-free survival; secondary end points include eval-
uation of the renal resistance index as an outcome predictor
after stent placement and the benefit of stent placement in
important patient subgroups, including women, African
Americans, diabetic patients, and those with bilateral ste-
nosis. RADAR plans to recruit 300 patients with impaired
renal function and ARAS estimated at 70% by Doppler
indices. The primary end point will be the change in renal
function; clinical and echographic cardiac outcomes are
secondary end points of the study.
CONCLUSION
Impaired renal function associated with ARAS is prob-
ably more stable over time than previously thought. Con-
versely, potential complications of stent placement for
ARAS are often underestimated. The results of recent
RCTs show that optimal medical treatment should be the
preferred option for most patients with ARAS: antihyper-
tensive agents including an ACE inhibitor or angiotensin-
receptor blocker, a statin, and an antiplatelet agent. Results
of ongoing trials are awaited to properly address the role of
stenting in patients with severe anatomic disease and to
look for an effect of stent placement on left ventricular
hypertrophy, beyond blood pressure lowering. Only patho-
physiologic rationale and anecdotal evidence support com-
pelling indications for revascularization in ARAS, including
rapidly progressive hypertension or renal failure, and flash
pulmonary edema.
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Volume 51, Number 6 Steichen et al 1580.e1Appendix 1 (online only). System used to rate the level
of evidence of individual studies.
● Level I: Evidence obtained from at least one properly
designed randomized controlled trial.
● Level II-1: Evidence obtained from well-designed
controlled trials without randomization.
● Level II-2: Evidence obtained from well-designed co-
hort or case-control analytic studies, preferably from
more than one center or research group.
● Level II-3:Evidenceobtainedfrommultiple timeserieswith
or without the intervention. Dramatic results in uncon-
trolled trials might also be regarded as this type of evidence.
● Level III: Opinions of respected authorities, based on
clinical experience, descriptive studies, or reports of
expert committees.
Appendix 2 (online only). Complications of renal artery
stenting
Between 10% and 20%
Vascular access complications, including
● Groin hematoma
● False aneurysm
● Bleeding requiring transfusion
● Arterial injury
● Puncture site infection
● Arterial thrombosis● Arteriovenous fistulaKidney injury and deterioration of renal function, including
● Contrast nephropathy
● Cholesterol atheroembolism
● Renal infarction
● Perirenal or retroperitoneal hematoma
Between 2% and 10%
Renal artery complications, including
● Dissection
● Stent misplacement or dislodgment
● Early restenosis
● Rupture or perforation
● Thrombosis
● Spasm
Periprocedural cardiovascular events, including:
● Nonrenal arterial embolization
● Pulmonary edema
● Myocardial infarction
● Venous thromboembolism
Less than 2%
Death by day 30, related to
● Myocardial infarction
● Stroke
● Pulmonary embolism
● Cholesterol embolism
● Hemorrhage
● SepticemiaContrast medium allergy
